Playback speed
10 seconds
ESMO GI 2024 Insights: 1L Unresectable HCC - Outcomes by Comorbidities With STRIDE (Durvalumab & Tremelimumab Regimen) in the HIMALAYA Study
By
Insights from 2024 ESMO GI Annual Meeting
FEATURING
Lorenza Rimassa
By
Insights from 2024 ESMO GI Annual Meeting
FEATURING
Lorenza Rimassa
0 views
July 5, 2024
Comments 0
Login to view comments.
Click here to Login